OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
178056

Allied Biotech Corp

Food ProcessingVerified

Allied Biotech Corp maintains a strong liquidity position, with cash and equivalents amounting to TWD 789.08 million, representing 37.7% of total assets. The company's liquidity FPT (free cash flow to total liabilities) is robust, with a current ratio of 1.9 and a debt-to-equity ratio of 0.59, indicating a conservative capital structure. Profitability metrics show a return on equity (ROE) of 10.49% and a return on assets (ROA) of 6.19%, both exceeding the typical thresholds for the Food Processing industry. The company's operating margin is 14.16% (operating income of TWD 120.34 million on revenue of TWD 849.51 million), suggesting efficient cost management and pricing power. The company's revenue is primarily derived from nutraceutical and carotenoid products, with a focus on food and beverage applications. While geographic exposure is not explicitly detailed, the company distributes products domestically and internationally, including to Asia, Europe, and the Americas. No single customer or region is disclosed to account for more than 10% of revenue. Looking ahead, the company is projected to maintain stable revenue growth, with a current FY outlook of 3.2% and a next FY outlook of 4.1%. This growth is supported by a strong free cash flow of TWD 60.85 million and a capital expenditure of TWD -33.58 million, indicating disciplined reinvestment. Risk factors are minimal, with low liquidity and dilution risk scores. No immediate filing-based liquidity or dilution flags were detected, and the company has not issued additional shares in the past 12 months. The absence of dilution pressure is reinforced by the fact that shares outstanding (basic and diluted) remain unchanged at 96.24 million. Recent events include the company's continued focus on R&D and product diversification, particularly in the nutraceutical and biotechnology segments. No material regulatory or geopolitical events have been disclosed in the latest filings, and the company remains well-positioned to capitalize on growing demand for natural and functional food ingredients.

30-day price · 1780+5.10 (+19.2%)
Low$25.60High$35.50Close$31.60As of15 May, 00:00 UTC
Profile
CompanyAllied Biotech Corp
Ticker1780.TWO
SectorConsumer Non-Cyclicals
BusinessFood & Beverages
Industry groupFood & Beverages
IndustryFood Processing
AI analysis

Business. Allied Biotech Corp develops, produces, and sells carotenoid and nutraceutical products, including beta-carotene, canthaxanthin, lycopene, and natural vitamin E, primarily for food and beverage applications, as well as pharmaceutical and animal health markets.

Classification. Allied Biotech Corp is classified under the Consumer Non-Cyclicals economic sector, Food & Beverages business sector, and Food Processing industry, with a confidence level of 0.92.

Allied Biotech Corp maintains a strong liquidity position, with cash and equivalents amounting to TWD 789.08 million, representing 37.7% of total assets. The company's liquidity FPT (free cash flow to total liabilities) is robust, with a current ratio of 1.9 and a debt-to-equity ratio of 0.59, indicating a conservative capital structure. Profitability metrics show a return on equity (ROE) of 10.49% and a return on assets (ROA) of 6.19%, both exceeding the typical thresholds for the Food Processing industry. The company's operating margin is 14.16% (operating income of TWD 120.34 million on revenue of TWD 849.51 million), suggesting efficient cost management and pricing power. The company's revenue is primarily derived from nutraceutical and carotenoid products, with a focus on food and beverage applications. While geographic exposure is not explicitly detailed, the company distributes products domestically and internationally, including to Asia, Europe, and the Americas. No single customer or region is disclosed to account for more than 10% of revenue. Looking ahead, the company is projected to maintain stable revenue growth, with a current FY outlook of 3.2% and a next FY outlook of 4.1%. This growth is supported by a strong free cash flow of TWD 60.85 million and a capital expenditure of TWD -33.58 million, indicating disciplined reinvestment. Risk factors are minimal, with low liquidity and dilution risk scores. No immediate filing-based liquidity or dilution flags were detected, and the company has not issued additional shares in the past 12 months. The absence of dilution pressure is reinforced by the fact that shares outstanding (basic and diluted) remain unchanged at 96.24 million. Recent events include the company's continued focus on R&D and product diversification, particularly in the nutraceutical and biotechnology segments. No material regulatory or geopolitical events have been disclosed in the latest filings, and the company remains well-positioned to capitalize on growing demand for natural and functional food ingredients.
Key takeaways
  • Allied Biotech Corp maintains a conservative capital structure with a debt-to-equity ratio of 0.59 and a current ratio of 1.9.
  • The company's ROE of 10.49% and ROA of 6.19% indicate strong profitability relative to industry norms.
  • Revenue is diversified across nutraceutical and carotenoid products, with international distribution channels.
  • The company is projected to grow revenue by 3.2% in the current fiscal year and 4.1% in the next.
  • Low liquidity and dilution risk scores suggest a stable financial position with no immediate capital-raising pressures.
  • --
  • # RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyTWD
Revenue$849.5M
Gross profit$308.6M
Operating income$120.3M
Net income$129.5M
R&D
SG&A
D&A
SBC
Operating cash flow$217.1M
CapEx-$33.6M
Free cash flow$60.8M
Total assets$2.09B
Total liabilities$857.2M
Total equity$1.23B
Cash & equivalents$789.1M
Long-term debt$731.9M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$1.23B
Net cash$57.2M
Current ratio1.9
Debt/Equity0.6
ROA6.2%
ROE10.5%
Cash conversion1.7%
CapEx/Revenue-4.0%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Food Processing · cohort 6 companies
Metric1780Activity
Op margin14.2%3.3% medp25 2.5% · p75 4.5%top quartile
Net margin15.2%3.0% medp25 1.5% · p75 6.7%top quartile
Gross margin36.3%24.0% medp25 20.2% · p75 35.3%top quartile
R&D / revenue0.8% medp25 0.5% · p75 2.3%
CapEx / revenue-4.0%5.2% medp25 4.8% · p75 5.7%bottom quartile
Debt / equity59.0%33.5% medp25 29.1% · p75 81.5%above median
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 08:48 UTC#230b86e5
Market quoteclose TWD 32.00 · shares 0.10B diluted
no public URL
2026-05-05 20:52 UTC#ffc82a1c
Source: analysis-pipeline (hybrid)Generated: 2026-05-10 08:50 UTCJob: 3c35cefc